News & Events

Simpson Thacher represented the independent directors of Quintiles Transnational Holdings Inc. (NYSE: Q) in its announced merger of equals with IMS Health Holdings, Inc. (NYSE: IMS). The merged company will be named Quintiles IMS Holdings, Inc. Based on the closing of IMS Health and Quintiles common stock prices on May 2, the equity market capitalization of the joined companies is more than $17.6 billion and the enterprise value is more than $23 billion. Under the terms of the merger agreement, IMS Health shareholders will receive a fixed exchange ratio of 0.384 shares of Quintiles common stock for each share of IMS Health common stock. Upon completion of the merger, IMS Health shareholders will own approximately 51.4% of the shares of the combined company on a fully diluted basis and Quintiles shareholders will own approximately 48.6% of the combined company on a fully diluted basis.

Quintiles helps biopharma and other healthcare companies improve their probability of success by connecting insights from their deep scientific, therapeutic and analytics expertise with superior delivery for better outcomes. From advisory through operations, Quintiles is the world’s largest provider of product development and integrated healthcare services, including commercial and observational solutions.

IMS Health is a leading global information and technology services company providing clients in the healthcare industry with end-to-end solutions to measure and improve their performance.

The Simpson Thacher team included Gary Horowitz, Marni Lerner, Nishal Ramphal and Catherine Burns (M&A).